Back to top
more

Evolent Health (EVH)

(Delayed Data from NYSE)

$4.49 USD

4.49
2,840,282

-0.18 (-3.85%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $4.49 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 247)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CrowdStrike (CRWD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

CrowdStrike (CRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Wall Street Analysts Believe Evolent Health (EVH) Could Rally 77.45%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 77.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Evolent Health (EVH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 55.56% and 1.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolent Health (EVH) Beats Q1 Earnings Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 40% and 1.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Centene (CNC) Expands Evolent Partnership to Boost Quality

by Zacks Equity Research

Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.

Zacks Equity Research

Evolent Health (EVH) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EngageSmart (ESMT) Matches Q4 Earnings Estimates

by Zacks Equity Research

EngageSmart (ESMT) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down 29.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolent Health (EVH)

by Zacks Equity Research

Evolent Health (EVH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Evolent Health (EVH) Q3 Earnings Top Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 637.50% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?